ARGX Share Price Performance
€0
-488.20 (-100.00%)
Price €0
Fair Value€839.27
Share Pricen/a
argenx SE Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 71 Fair Values set on narratives written by author
ARGX Community Narratives
AN
Fair Value €839.27 18.7% undervalued intrinsic discount
ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook
0users have liked this narrative
0users have commented on this narrative
30users have followed this narrative
AN
Fair Value €991 31.2% undervalued intrinsic discount
AI Collaboration And Aging Trends Will Expand Autoimmune Biologics Markets
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value €614.8 10.9% overvalued intrinsic discount
Rising Pricing Pressures And Biosimilar Challenges Will Weaken Margins
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AI Collaboration And Aging Trends Will Expand Autoimmune Biologics Markets
Key Takeaways Rapid Vyvgart adoption, expanded indications, and accelerated self-administration are driving market expansion, revenue growth, and margin improvement well beyond initial expectations. Advancements in drug discovery and strong financial position enable swift pipeline development, supporting long-term leadership and outperformance in rare autoimmune biologics.Read more
46
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
€991
31.2% undervalued intrinsic discount
Fair Value
Revenue
33.76% p.a.
Profit Margin
38.91%
Future PE
22.28x
Price in 2029
€1.16k
ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook
Key Takeaways Broadening indications and effective global expansion for Vyvgart, alongside pipeline progress, are driving strong, sustained revenue and margin growth. Strategic partnerships and advances in disease targeting are expanding market opportunities and operational efficiencies, supporting long-term growth potential.Read more
387
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
30users have followed this narrative
AN
€839.27
18.7% undervalued intrinsic discount
Fair Value
Revenue
25.95% p.a.
Profit Margin
35.18%
Future PE
24.52x
Price in 2029
€991.27
Rising Pricing Pressures And Biosimilar Challenges Will Weaken Margins
Key Takeaways Reliance on Vyvgart and vulnerability to biosimilar competition risk future revenue, margin stability, and long-term market share. Growing regulatory, pricing, and supply chain pressures threaten profitability and the ability to meet international expansion goals.Read more
34
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
€614.8
10.9% overvalued intrinsic discount
Fair Value
Revenue
26.41% p.a.
Profit Margin
36.48%
Future PE
19.46x
Price in 2029
€715.91
Trending Discussion
Recently Updated Narratives
AN
ARGX: Graves And gMG Expansion Will Drive Future Repricing Potential
Fair Value: €991 31.2% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ARGX: Late Stage Neuromuscular Pipeline Readouts Will Drive Future Upside
Fair Value: €839.27 18.7% undervalued intrinsic discount
30 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ARGX: Future Sector Correlation Risk May Undermine Elevated Biotech Thesis
Fair Value: €614.8 10.9% overvalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
argenx SE Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 07, 2026
- 20.78
- 57.16%
- 30.50%
- 0%
About ARGX
- Founded
- 2008
- Employees
- 1863
- CEO
- WebsiteView website
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
